cervical cancer

Cervical cancer prevention in Morocco : a model-based cost-effectiveness analysis

Cervical cancer is a preventable disease. Despite this, the annual incidence globally is projected to increase from 570,000 cases currently to 700,000 by 2030, and most of these will be among young under-educated women in low- and middle-income countries (LMICs) (1, 2). The human papillomavirus (HPV) vaccine offers the potential to eliminate cervical cancer if routinely available and used based on recent studies (3). This is especially important in LMICs where the cost of cancer care can be prohibitive including biological medicines (4).